Significant Developments: China Biologic Products Holdings, Inc. (01177) has had its marketing application for Ropivacaine Hydrochloride Sustained-Release Solution accepted.
Mabwell (Shanghai) Bioscience Co., Ltd. (02335) has completed the enrollment of the first subject in the Ib/II phase clinical trial for MT1002 in the treatment of acute ischemic stroke.
GBA AI COMP (01396) has accumulated over RMB 15 billion in new intentional orders for its AI computing power cloud services in the first half of the year and expects an interim net profit of no less than RMB 240 million.
Ascletis Pharma Inc. (01672) has submitted two Investigational New Drug (IND) applications to the U.S. FDA for the treatment of obesity: the monthly injectable peptide amylin receptor agonist ASC36, and the ASC36_35 compound monthly injection combining ASC36 with the peptide GLP-1R/GIPR agonist ASC35.
Far East Consortium International Limited (00035) plans to sell a 100% stake in Jiecai for HKD 750 million through a subsidiary.
FS Innovation (03355) intends to acquire a 100% stake in Shanghai Boda Data Communication for RMB 330 million.
Xunce (03317) has entered into a strategic cooperation with Gechuang Dongzhi to jointly explore the AI data infrastructure Token factory model in the industrial intelligent manufacturing sector.
Gushengtang Health Technology Group Co., Ltd. (02273) plans to acquire controlling stakes in Shahe Hospital and Beijing Hongyang Hospital through a subsidiary.
China Isotope & Radiation Corporation (01763) has established a joint venture, CNNC Fuyuan, with China Nuclear Yuanke.
Ruifeng Power Group Co., Ltd. (02025) has officially commenced trial production of 4 ship cleaning robots, with delivery expected in August.
Operational Performance: China New Town Development Co., Ltd. (01278) reported that the total value of its fixed-income project investment portfolio was approximately RMB 3.053 billion as of the end of June.
H&H International Holdings Limited (01112) achieved a double-digit year-on-year increase in total revenue for the first six months.
Chuangxin Industrial (02788) issued a positive profit alert, expecting an interim net profit between RMB 2.2 billion and RMB 2.4 billion, representing an increase of approximately 154.1% to 177.2% year-on-year.
Guotai Haitong (02611) issued a positive profit alert, anticipating an interim attributable net profit of RMB 20.003 billion to RMB 20.511 billion, a year-on-year increase of 27% to 30%.
Greentown Management Holdings Limited (09979) reported that the estimated management fees for new project contracts secured in the first half of the year were RMB 3.41 billion, a decrease of about 31.7% year-on-year.
Kangning Hospital Co., Ltd. (02120) reported an average total outpatient expenditure of RMB 303 per visit in the second quarter, a 9.0% increase year-on-year.